Article
Litigation Trends—securities Litigation In A Danish Context
Evidence of this is readily available in the U.S., where Novo Nordisk is currently facing multiple class action lawsuits from investors alleging disclosure failures relating to GLP-1 products and the weight-loss drug CagriSema.
A&O Shearman